Fac­ing fears of neu­ronal dam­age, No­var­tis slams brakes on Hunt­ing­ton's tri­al

No­var­tis has sus­pend­ed dos­ing in a Hunt­ing­ton’s dis­ease study af­ter safe­ty sig­nals emerged that point to po­ten­tial side ef­fects on pa­tients’ nerves.

Specif­i­cal­ly, the drug­mak­er wrote in a let­ter shared with the Hunt­ing­ton’s Dis­ease So­ci­ety of Amer­i­ca, there are con­cerns that “branaplam might be caus­ing pe­riph­er­al neu­ropa­thy, which re­sults from in­jury to the nerves lo­cat­ed out­side of the brain and spinal cord.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER